NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for NUVA
54.93
+0.34 (0.62%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.54 - 55.09
52 week 33.33 - 55.66
Open 54.59
Vol / Avg. 920,840.00/501,770.00
Mkt cap 2.67B
P/E 59.17
Div/yield     -
EPS 0.93
Shares 48.94M
Beta 0.96
Inst. own 106%
Oct 28, 2015
Q3 2015 NuVasive Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 28, 2015
Q2 2015 NuVasive Inc Earnings Call - Webcast
Jul 28, 2015
Q2 2015 NuVasive Inc Earnings Release
Jun 30, 2015
NuVasive�, Inc. at the Nasdaq 32nd Investor Program - Webcast
Jun 12, 2015
NuVasive Inc Annual Shareholders Meeting - Webcast
Jun 10, 2015
NuVasive Inc at Goldman Sachs Healthcare Conference
Jun 1, 2015
NuVasive Inc at Jefferies Global Healthcare Conference - Webcast
May 19, 2015
NuVasive�, Inc. at the UBS Global Healthcare Conference - Webcast
May 12, 2015
NuVasive�, Inc. at the Bank of America 2015 Healthcare Conference - Webcast
May 4, 2015
Q1 2015 NuVasive Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 4.95% -2.29%
Operating margin 12.75% 2.38%
EBITD margin - 16.36%
Return on average assets 3.12% -1.39%
Return on average equity 6.23% -2.71%
Employees 1,500 -
CDP Score - -

Address

7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Company’s software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Patrick W. G. Miles President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Executive Vice President
Age: 36
Bio & Compensation  - Reuters
Jason M. Hannon Executive Vice President - International, General Counsel
Age: 43
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link Executive Vice President - U.S. Sales
Age: 40
Bio & Compensation  - Reuters
Mike Paolucci Executive Vice President - Global Human Resources
Age: 54
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - Strategy, Corporate Development, External
Age: 50
Bio & Compensation  - Reuters
Peter Michael Leddy Ph.D. Executive Vice President - Human Resources and Corporate Integrity
Age: 51
Bio & Compensation  - Reuters
Russell Powers Executive Vice President - International
Age: 45
Bio & Compensation  - Reuters
Daniel J. Wolterman Director
Age: 58
Bio & Compensation  - Reuters